An advisory panel to the FDA has recommended Johnson & Johnson's experimental nasal spray, which has a compound similar to often-abused ketamine, for patients suffering from depression.


Greater depressive and anxiety symptoms at baseline predicted a better response to treatment with synchronized transcranial magnetic stimulation (sTMS) for major depressive disorder (MDD), according to a study.

Older adults who are prescribed medication for depression by primary care physicians often fail to initiate them or to continue using them as directed, a Dutch study suggests.

Adjunctive testosterone treatment in men is associated with a significant drop in depressive symptoms, compared with placebo, according to a systematic review and meta-analysis published online in JAMA Psychiatry.

More frequent in-person social interaction is linked with a significantly lower risk of symptoms of major depression and posttraumatic stress disorder (PTSD) in US military veterans, according to a study published online.

Depression appears to be linked with an increased risk of developing inflammatory bowel disease (IBD), but antidepressant use might bring that risk back down, researchers in Canada report.



Psychedelic compounds are powerful, and they have great potential to help patients with intractable conditions. Yet any compound with that kind of power also has the potential to harm, and that harm should not be trivialized.

This year at orientation, there was a huge elephant in the room.

Perhaps patients would benefit if they had some concrete saying, a mantra as it were, to remind themselves outside the therapy room of key lessons.



Alex Kopelowicz, MD; Ross A. Baker, PhD, MBA; Cathy Zhao, PhD, MS, BS; Raymond Sanchez, MD; Margaretta Nyilas, MD; Claudette Brewer, BA; Erica Lawson; Timothy Peters-Strickland, MD
Andrew Valadez, BS; Rustin Berlow, MD
Martha Sajatovic, MD; Andrew Cutler, MD; Khodayar Farahmand, PharmD; Joshua Burke, MS; Scott Siegert, PharmD; Grace Liang, MD
Faisal Kagadkar, MBBS; Shanila Taha, MBBS; Venkatesh Sreeram, MBBS



David E. Nichols, PhD, talks with Charles Raison, MD, about how ketamine works at the receptor level to produce powerful and rapid antidepressant effects. Click through to watch the video and read a transcript.

Charles Raison, MD, interviews Gerard Sanacora, MD, PhD, about a common clinical scenario—a patient in your office requests ketamine, an experimental treatment. What do you do?